Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load

Bibliographic Details
Main Author: LIN Bingliang
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2021-04-01
Series:Linchuang Gandanbing Zazhi
Online Access:http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.009
id doaj-ca016c6d30fb484e9f77799a5a3fbbc9
record_format Article
spelling doaj-ca016c6d30fb484e9f77799a5a3fbbc92021-04-26T08:13:42ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562021-04-01374778780Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral loadLIN Bingliang0The Third Affiliated Hospital of Sun Yat-Sen Universityhttp://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.009
collection DOAJ
language zho
format Article
sources DOAJ
author LIN Bingliang
spellingShingle LIN Bingliang
Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
Linchuang Gandanbing Zazhi
author_facet LIN Bingliang
author_sort LIN Bingliang
title Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
title_short Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
title_full Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
title_fullStr Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
title_full_unstemmed Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
title_sort patients in the immune-tolerant phase of hepatitis b virus infection should receive antiviral therapy to reduce viral load
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2021-04-01
url http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.009
work_keys_str_mv AT linbingliang patientsintheimmunetolerantphaseofhepatitisbvirusinfectionshouldreceiveantiviraltherapytoreduceviralload
_version_ 1721507736677515264